Ground News

News from FDA Law Blog

Stay current with all the latest and breaking news from FDA Law Blog. Compare headlines and media bias behind news outlets on stories breaking today.

In total, 45 have been published by FDA Law Blog which Ground News has aggregated in the past 3 months.

Ground News rates FDA Law Blog’s media bias as unknown. Ground News is unable to assign a bias rating and does not have ratings available from Ad Fontes Media, All Sides, and Media Bias/Fact Check.

FDA Law Blog’s factuality rating is Unknown. Ground News calculates this rating using a combination of the fact and reliability ratings from Ad Fontes Media and Media Bias/Fact Check.

Information about FDA Law Blog

Where is FDA Law Blog located?FDA Law Blog's Website

Media Bias Ratings

Do you diasgree?

Edit bias

Learn more about Media Bias Ratings.

Factuality

Learn more about Factuality Ratings

Reveal Factuality Ratings by upgrading to a Premium account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Ownership

Learn more about Ownership categories

Reveal Ownership Data by upgrading to a Vantage account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Top FDA Law Blog News

FDA · United States

FDA to offer faster drug reviews to companies promoting ‘national priorities’

66% Center coverage: 63 sources

See the Story

Increasing Biosimilar Use Reflects Changing Practice in Pediatric IBD Care

Pediatric infliximab biosimilar use has risen significantly, reflecting evolving treatment patterns in inflammatory bowel disease (IBD) among children and young adults.See the Story

Rockville, Maryland · Rockville

FDA Issues Proposed Order to Facilitate Minor Changes to Solid Oral Dosage Forms to OTC Monograph Drugs, but Such Changes May Come at a Price

On June 5, 2025, FDA announced two proposed monograph orders: 1) Proposed order OTC000038 proposes to make it easier to make (minor) changes to solid oral dosage forms not currently permitted under…Read Article

DEA Cranks Out Updated Special Surveillance List and Proposed Regulatory Actions

By Larry K. Houck —Special Surveillance List of Chemicals, Products, Materials and Equipment Updated A “laboratory supply” is any List I or List II chemical, or any chemical, substance, or other item on a special surveillance list published by the Attorney General (delegated to the Drug Enforcement Administration (“DEA”)) of chemicals, products, materials, or equipment used in the illicit manufacture of controlled substances and listed chemicals…DEA · United States Read Article

Clinical Research Representation: Pass it On

Thirty two years ago today, on June 10, 1993, Congress passed the landmark National Institutes of Health (NIH) Revitalization Act to remedy historical exclusion of women and minorities from researc…FDA Read Article

FTC Rejects Meta’s Accusation of Biased Economics Expert in Antitrust Trial - USA Herald

The Federal Trade Commission (FTC) on Friday urged a Washington, D.C. federal judge to reject Meta Platforms Inc.’s attempt to strike the testimony of the agency’s lead economics expert, dismissing Meta’s accusation of bias as unfounded and without legal merit. In an opposition brief filed with the court, the FTC criticized Meta for avoiding the substantive issues of the case by launching “personal attacks and misdirection” against New York Univ…FTC · United States See the Story

Time is Money and Money is Time…What is an SBD Worth?

We have written many posts (here, here, here, and more) about the impact of the reductions in force (RIFs) on various activities across FDA. One area where the RIFs are beginning to have an impact …Money · Silver Spring Read Article

MAHA Analysis Reveals Impact on Drug Scheduling and Abuse-Deterrent Product Development

A recent analysis of the Mandatory Human Abuse Liabilit […] The post MAHA Analysis Reveals Impact on Drug Scheduling and Abuse-Deterrent Product Development first appeared on GeneOnline News. The post MAHA Analysis Reveals Impact on Drug Scheduling and Abuse-Deterrent Product Development appeared first on GeneOnline News.United States · United States See the Story

Two “Unresolvable” Prescribing/Dispensing Red Flags Unfurled

We appreciate receiving feedback on our blog posts. We received a response to our post on the prescribing red flags indicating the likelihood of certain prescriptions filled by Walgreens pharmacie…Chicago, IL · Chicago Read Article

FDA Abandons Its Defense of the LDT Rule, But is It Signaling an Increase in RUO Scrutiny?

At midnight on Friday, May 30, 2025, the government’s deadline to notice an appeal from the U.S. District Court for the Eastern District of Texas’s decision vacating the LDT Rule lapsed without the…Texas, United States · Texas Read Article

Senator Durbin Has Questions About FDA’s “Operational Capacity” to Oversee DTC Prescription Drug Advertising Amid Workforce Reductions – Don’t We All?

In a recent letter to FDA Commissioner Dr. Martin Makary, U.S. Senator Dick Durbin (D-IL) expressed concerns over the agency’s ability to regulate direct-to-consumer (“DTC”) prescription drug adver…Washington · Washington Read Article

News from FDA Law Blog

News from FDA Law Blog

Information about FDA Law Blog

Media Bias Ratings

Factuality

Ownership

Top FDA Law Blog News

FDA to offer faster drug reviews to companies promoting ‘national priorities’

Increasing Biosimilar Use Reflects Changing Practice in Pediatric IBD Care

FDA Issues Proposed Order to Facilitate Minor Changes to Solid Oral Dosage Forms to OTC Monograph Drugs, but Such Changes May Come at a Price

DEA Cranks Out Updated Special Surveillance List and Proposed Regulatory Actions

Clinical Research Representation: Pass it On

FTC Rejects Meta’s Accusation of Biased Economics Expert in Antitrust Trial - USA Herald

Time is Money and Money is Time…What is an SBD Worth?

MAHA Analysis Reveals Impact on Drug Scheduling and Abuse-Deterrent Product Development

Two “Unresolvable” Prescribing/Dispensing Red Flags Unfurled

FDA Abandons Its Defense of the LDT Rule, But is It Signaling an Increase in RUO Scrutiny?

Senator Durbin Has Questions About FDA’s “Operational Capacity” to Oversee DTC Prescription Drug Advertising Amid Workforce Reductions – Don’t We All?

Similar News Topics

Topics Most Covered by FDA Law Blog

Sources Covering Similar Topics

Breaking News Topics Related to FDA Law Blog